Early testing of AK152 in healthy people and mild Alzheimer's
Part of Brain & nervous system clinical trials.
This early-stage trial tests a new medicine called AK152 in two groups: healthy volunteers and people with Alzheimer's disease or mild memory problems. For Alzheimer's patients, the study looks at whether the drug safely targets amyloid plaques in the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Healthy volunteers must be 18–40 years old.
- Alzheimer's patients must be 50–85 years old.
- Alzheimer's patients need a PET scan showing amyloid protein in the brain.
- Alzheimer's patients must have a caregiver or study partner who can join visits.
- Participants must not have had a stroke in the last 12 months.
- Women must not be pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This trial tests a new investigational drug, BMS-986446, given as a single dose to healthy volunteers and multiple doses to people with early Alzheimer's disease. It aims to understand how the drug moves in the body, its safety, and whether it triggers an immune response, which could help guide future treatment for Alzheimer's.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This Phase 1 trial tests how safe and tolerable ALN-APP is in people with early Alzheimer’s-related mild memory impairment or mild dementia. It may help researchers find a treatment path for early Alzheimer’s, while closely monitoring side effects and basic health markers.
This trial tests a new investigational drug called CM383, which is a type of antibody (a protein that helps the immune system) possibly targeting brain plaque linked to Alzheimer's disease. It is an early-stage study in healthy volunteers to check safety and how the drug behaves in the body.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.
Hear when a new Alzheimer s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.